CD134/OX40/TNFRSF4/Txgp1
Alpha Lifetech can provide CD134/OX40/TNFRSF4/Txgp1 corresponding products, help each customer's research and development.
01
Introduction To CD134/OX40/TNFRSF4/Txgp1
Drug targetis a biomolecule that can directly bind to drugs and then react. Generally, the target refers to protein, which is related to the cause of disease. The focus of the target began with focusing on tumors, and then began to spread to various fields. CD134/OX40/TNFRSF4/Txgp1 protein is a common target in medicine.
Function of Target CD134/OX40/TNFRSF4/Txgp1
CD134 belongs to a member of the TNF receptor family, also known as OX 40, Txgp 1 and TNFRSF4, also known as the tumor necrosis factor receptor superfamily member 4, is a transmembrane glycoprotein of 50 kDa, typed as type I. OX 40 is generally expressed on already activated T lymphocytes. The interaction between OX 40 and OX 40 L will affect the body, which will lead to the proliferation of B cells and antibody secretion, It can also affect the proliferation and differentiation of the primary T cells and provide the survival rate of the T cells.OX 40 is a co-stimulatory molecule that is also mainly expressed on activated various immune cells and, in addition to that, on activated antigen-presenting cells.
Gene Pathway of Target CD134/OX40/TNFRSF4/Txgp1
OX40L is a hexamer complex, which is composed of a trimer and three OX40 proteins, which affect the genes of T cell division and survival by activating downstream NF-κB, PI3K and AKT signaling pathways, and further promote the transcription of cytokine genes and the expression of cytokine receptors, which is very important for cell survival.
OX 40 and mutual influence between OX 40 L, TNFR related (TRAFs) can affect CD4 + T cell tolerance to the regulation of the OX 40 intracellular domain, TRAF family activate NF- κ B and other signaling pathways, cause the effector T cells and prolong survival time, inhibit the differentiation and activity of regulatory T cells, promote and maintain CD4 + cell memory, promote the generation of memory CD8 + cells, interact with a variety of pro-inflammatory mediators, improve autoimmunity in the body.
OX 40 can increase the survival rate of various types of CD cells and promote the expression of cytokines such as interleukin by enhancing the signaling conduction, which causes the T cell immune response of the tumor cells, and then eliminates the tumor cells.On the contrary, if we block the binding of OX 40 to OX 40 L, we can change the antigen-specific T cell response produced by the body itself and reduce the immune activity of self-free disease. Therefore, OX 40 / OX 40 L inhibitors have therapeutic potential for autoimmune diseases.
This biological characteristic of OX 40 means that it is expected to bring therapeutic effects on a variety of immune system diseases, such as tumors, organ transplantation, asthma, and autoimmune diseases. Currently, drug development for OX 40 focuses on the field of cancer and self-free disease.
Fig 1: CD134 Gene Pathway. (Reference documentation: Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol. 2010;28:57-78.)
Alpha Lifetech Can Provide
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ALP64666 | 50ug,100ug,500ug | |
| ALP64657 | 50ug,100ug,500ug | |
| ALP64635 | 50ug,100ug,500ug | |
| ALP64614 | 50ug,100ug,500ug | |
| ALP64613 | 50ug,100ug,500ug | |
| ALP64609 | 50ug,100ug,500ug | |
| ALP64572 | 50ug,100ug,500ug | |
| ALP64561 | 50ug,100ug,500ug | |
| ADT1155 | ADT1155-Cudarolimab Biosimilar– Anti-CD134/OX40/TNFRSF4/ mAb – Research Grade |
100ug,1mg,5mg |
| ADT1548 | ADT1548-Revdofilimab Biosimilar– Anti-CD134/OX40/TNFRSF4/ mAb – Research Grade |
100ug,1mg,5mg |
| ADT1630 | ADT1630-Tavolixizumab Biosimilar– Anti-CD134/OX40/TNFRSF4/ mAb – Research Grade |
100ug,1mg,5mg |
| ADT1634 | ADT1634-Telazorlimab Biosimilar– Anti-CD134/OX40/TNFRSF4/ mAb – Research Grade |
100ug,1mg,5mg |
| ADT1707 | ADT1707-Vonlerizumab Biosimilar– Anti-CD134/OX40/TNFRSF4/ mAb – Research Grade |
100ug,1mg,5mg |
| ADT1330 | ADT1330-Ivuxolimab Biosimilar– Anti-CD134//TNFRSF4/ mAb – Research Grade |
1mg,5mg |
| ADT1708 | ADT1708-Vonlerolizumab Biosimilar– Anti-CD134/TNFRSF4/ mAb – Research Grade |
1mg,5mg |
Reference
[1] Gough MJ, Weinberg AD. OX40 (CD134) and OX40L. Adv Exp Med Biol. 2009;647:94-107.
[2] AWebb GJ, Hirschfield GM, Lane PJ. OX40, OX40L and Autoimmunity: a Comprehensive Review. Clin Rev Allergy Immunol. 2016 Jun;50(3):312-32.
[3] Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol. 2010;28:57-78.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102